CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.
CP, L., T, J., L, F., E, P., CH, R., JN, K., N, K., J, B., J, R., & H, Z. (2026). CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71720
CP L, T J, L F, E P, CH R, JN K, et al. CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026; doi: 10.1002/alz.71720
CP L, T J, L F, et al. CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.[J]. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. DOI: 10.1002/alz.71720.
@article{cp2026,
author = {Lisgaras CP and Jacobs T and Figueredo L and Pirraglia E and Radtke CH and Keller JN and Karvelas N and Bernal J and Ruiz J and Zetterberg H},
title = {CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71720},
note = {PMID: 42583778},
}
TY - JOUR AU - Lisgaras CP AU - Jacobs T AU - Figueredo L AU - Pirraglia E AU - Radtke CH AU - Keller JN AU - Karvelas N AU - Bernal J AU - Ruiz J AU - Zetterberg H TI - CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults. T2 - Alzheimer's & dementia : the journal of the Alzheimer's Association PY - 2026 DO - 10.1002/alz.71720 AN - PMID:42583778 ER -
INTRODUCTION: Blood-brain barrier (BBB) dysfunction is an early feature of Alzheimer's disease (AD). Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals remains unknown. METHODS: CU older adults underwent clinical evaluation and cerebrospinal fluid (CSF) assessment of fibrinogen, Aβ42, total tau (tTau), phosphorylated tau 181 (pTau181), and YKL-40. Linear regression tested baseline associations. Linear mixed-effects models tested whether baseline fibrinogen predicted longitudinal pTau181 change. RESULTS: Among 169 CU participants with baseline fibrinogen, 87 had longitudinal pTau181 measurements (mean follow-up 2.5-years). Higher fibrinogen was associated with elevated YKL-40 (β = 0.28, 95% confidence interval [CI] [0.11, 0.45]) but not Aβ42, tTau, or pTau181 at baseline. Baseline fibrinogen modified longitudinal pTau181 trajectories (interaction β = 0.11, 95% CI [0.04, 0.19]), with only participants above the median showing significant pTau181 increases (β = 0.13, 95% CI [0.08, 0.18]). DISCUSSION: CSF fibrinogen associates cross-sectionally with glial inflammation and predicts accelerated tau accumulation in preclinical AD.